Bragar Eagel & Squire, P.C. Urgently Reminds Investors of Cytokinetics, Quanex, Freeport, and Primo Brands to Contact the Firm About their RightsNEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Cytokinetics, Incorporated (
NASDAQ:CYTK), Quanex Building Products Corporation (
NYSE:NX), Freeport-McMoran Inc. (
NYSE:FCX), and Primo Brands Corporation (
NYSE:PRMB). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action LawsuitNEW YORK - November 17, 2025 ( NEWMEDIAWIRE ) - Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (
NASDAQ: CYTK) and certain of its officers.
CYTK FINAL DEADLINE: Faruqi & Faruqi, LLP Announces that Cytokinetics Investors Have Opportunity to Lead Class Action Lawsuit
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (
NASDAQ: CYTK) and reminds investors of the November 17, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (
NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
